托法替布作为难治性神经结节病的维持治疗药物。 - Suppr

Suppr

超能文献

Tofacitinib as maintenance therapy for refractory Neurosarcoidosis.

作者信息

de Melo Bandeira Maria Ciravegna Fonseca, Van Pesch Vincent, Onofrj Valeria, Lawson Tévi Morel, Yildiz Halil

机构信息

Department of Neurology, Cliniques Universitaires Saint-Luc, UCLouvain, Avenue Hippocrate 10, 1200, Brussels, Belgium.

Department of Radiology, Cliniques Universitaires Saint-Luc, UCLouvain, Avenue Hippocrate 10, 1200, Brussels, Belgium.

出版信息

Acta Neurol Belg. 2025 Jun;125(3):829-831. doi: 10.1007/s13760-024-02680-0. Epub 2024 Nov 6.

DOI:10.1007/s13760-024-02680-0

PMID:39503837

Abstract

摘要

相似文献

Tofacitinib as maintenance therapy for refractory Neurosarcoidosis.

Acta Neurol Belg. 2025 Jun;125(3):829-831. doi: 10.1007/s13760-024-02680-0. Epub 2024 Nov 6.

Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series.

Therap Adv Gastroenterol. 2025 Mar 30;18:17562848251323511. doi: 10.1177/17562848251323511. eCollection 2025.

Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis.

Clin Kidney J. 2024 Apr 25;17(5):sfae127. doi: 10.1093/ckj/sfae127. eCollection 2024 May.

Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab.

Acta Neurol Scand. 2007 Oct;116(4):259-62. doi: 10.1111/j.1600-0404.2007.00870.x.

Neurosarcoidosis.

Curr Treat Options Neurol. 2013 Aug;15(4):492-504. doi: 10.1007/s11940-013-0242-9.

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

J Crohns Colitis. 2022 Jan 28;16(1):166-168. doi: 10.1093/ecco-jcc/jjab109.

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.

J Med Econ. 2021 Jan-Dec;24(1):279-290. doi: 10.1080/13696998.2021.1881323.

Medically refractory neurosarcoidosis treated with infliximab.

Intern Med J. 2011 Apr;41(4):354-7. doi: 10.1111/j.1445-5994.2011.02457.x.

Intractable Neurosarcoidosis Effectively Treated with Infliximab.

Intern Med. 2016;55(7):811-4. doi: 10.2169/internalmedicine.55.5506. Epub 2016 Apr 1.

Neurosarcoidosis-induced winging scapula: Efficacy of infliximab treatment in addressing multifaceted challenges.

Mod Rheumatol Case Rep. 2025 Jan 16;9(1):184-187. doi: 10.1093/mrcr/rxae030.

本文引用的文献

Neurosarcoidosis: Diagnostic Challenges and Mimics A Review.

Curr Allergy Asthma Rep. 2023 Jul;23(7):399-410. doi: 10.1007/s11882-023-01092-z. Epub 2023 May 31.

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Tofacitinib as maintenance therapy for refractory Neurosarcoidosis.

作者信息

de Melo Bandeira Maria Ciravegna Fonseca, Van Pesch Vincent, Onofrj Valeria, Lawson Tévi Morel, Yildiz Halil

机构信息

Department of Neurology, Cliniques Universitaires Saint-Luc, UCLouvain, Avenue Hippocrate 10, 1200, Brussels, Belgium.

Department of Radiology, Cliniques Universitaires Saint-Luc, UCLouvain, Avenue Hippocrate 10, 1200, Brussels, Belgium.

出版信息

Acta Neurol Belg. 2025 Jun;125(3):829-831. doi: 10.1007/s13760-024-02680-0. Epub 2024 Nov 6.

DOI:10.1007/s13760-024-02680-0

PMID:39503837

Abstract

摘要

相似文献

Tofacitinib as maintenance therapy for refractory Neurosarcoidosis.

Acta Neurol Belg. 2025 Jun;125(3):829-831. doi: 10.1007/s13760-024-02680-0. Epub 2024 Nov 6.

Sequential rescue therapy with JAK inhibitors in corticosteroid and infliximab-refractory acute severe ulcerative colitis: a case series.

Therap Adv Gastroenterol. 2025 Mar 30;18:17562848251323511. doi: 10.1177/17562848251323511. eCollection 2025.

Tofacitinib for the treatment of refractory immune checkpoint inhibitor-associated immune nephritis.

Clin Kidney J. 2024 Apr 25;17(5):sfae127. doi: 10.1093/ckj/sfae127. eCollection 2024 May.

Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab.

Acta Neurol Scand. 2007 Oct;116(4):259-62. doi: 10.1111/j.1600-0404.2007.00870.x.

Neurosarcoidosis.

Curr Treat Options Neurol. 2013 Aug;15(4):492-504. doi: 10.1007/s11940-013-0242-9.

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

J Crohns Colitis. 2022 Jan 28;16(1):166-168. doi: 10.1093/ecco-jcc/jjab109.

Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.

J Med Econ. 2021 Jan-Dec;24(1):279-290. doi: 10.1080/13696998.2021.1881323.

Medically refractory neurosarcoidosis treated with infliximab.

Intern Med J. 2011 Apr;41(4):354-7. doi: 10.1111/j.1445-5994.2011.02457.x.

Intractable Neurosarcoidosis Effectively Treated with Infliximab.

Intern Med. 2016;55(7):811-4. doi: 10.2169/internalmedicine.55.5506. Epub 2016 Apr 1.

Neurosarcoidosis-induced winging scapula: Efficacy of infliximab treatment in addressing multifaceted challenges.

Mod Rheumatol Case Rep. 2025 Jan 16;9(1):184-187. doi: 10.1093/mrcr/rxae030.

本文引用的文献

Neurosarcoidosis: Diagnostic Challenges and Mimics A Review.

Curr Allergy Asthma Rep. 2023 Jul;23(7):399-410. doi: 10.1007/s11882-023-01092-z. Epub 2023 May 31.

Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis.

Nat Commun. 2022 Jun 6;13(1):3140. doi: 10.1038/s41467-022-30615-x.